Ado-trastuzumab emtansine Side Effects
In Summary
Commonly reported side effects of ado-trastuzumab emtansine include: increased serum bilirubin, increased serum transaminases, cough, decreased platelet count, dyspnea, fatigue, fever, peripheral neuropathy, and thrombocytopenia. Other side effects include: chills. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to ado-trastuzumab emtansine: intravenous powder for solution
Along with its needed effects, ado-trastuzumab emtansine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking ado-trastuzumab emtansine:
More common- Black, tarry stools
- bladder pain
- bleeding gums
- bloating or swelling of the face, arms, hands, lower legs, or feet
- bloody or cloudy urine
- blurred vision
- burning, numbness, tingling, or painful sensations
- chills
- convulsions
- cough
- decreased urine
- difficult or labored breathing
- difficult, burning, or painful urination
- dizziness
- dry mouth
- fever
- frequent urge to urinate
- headache
- increased thirst
- irregular heartbeat
- loss of appetite
- lower back or side pain
- mood changes
- muscle pain or cramps
- nausea or vomiting
- nervousness
- nosebleeds
- numbness or tingling in the hands, feet, or lips
- pale skin
- pinpoint red spots on the skin
- pounding in the ears
- rapid weight gain
- slow or fast heartbeat
- sore throat
- tightness in the chest
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unsteadiness or awkwardness
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- weakness in the arms, hands, legs, or feet
- Chest pain
- dilated neck veins
- extreme fatigue
- general feeling of discomfort or illness
- irregular breathing
- irregular heartbeat
- skin rash
- thickening of bronchial secretions
- Dark-colored urine
- general feeling of tiredness or weakness
- light-colored stools
- stomach bloating or pain
- vomiting blood
- yellow eyes or skin
- Abdominal or stomach tenderness
- itching
Some side effects of ado-trastuzumab emtansine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common- Acid or sour stomach
- belching
- change in taste
- constipation
- diarrhea
- difficulty with moving
- heartburn
- indigestion
- lack or loss of strength
- loss of taste
- muscle pain or stiffness
- pain in the joints
- stomach discomfort or upset
- swelling or inflammation of the mouth
- trouble sleeping
- Burning, dry, or itching eyes
- discharge or excessive tearing
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
For Healthcare Professionals
Applies to ado-trastuzumab emtansine: intravenous powder for injection
Cardiovascular
Common (1% to 10%): Left ventricular dysfunction, hypertension, peripheral edema[Ref]
Dermatologic
Very common (10% or more): Rash (12%)
Common (1% to 10%): Pruritus, alopecia, nail disorder, palmar-plantar erythrodysesthesia syndrome, urticaria[Ref]
Gastrointestinal
Very common (10% or more): Nausea (40%), constipation (24%), vomiting (20%), diarrhea (20%), dry mouth (16%), abdominal pain (16%), stomatitis (15%), stomatitis
Common (1% to 10%): Dyspepsia, gingival bleeding[Ref]
Genitourinary
Very common (10% or more): Urinary tract infection (12%)[Ref]
Hematologic
Very common (10% or more): Hemorrhage (35%), thrombocytopenia (25%), anemia (15%), hemorrhage
Common (1% to 10%): Neutropenia, leucopenia[Ref]
Hepatic
Very common (10% or more): Transaminases increased (12%)
Common (1% to 10%):
Uncommon (0.1% to 1%): Hepatotoxicity, hepatic failure, nodular regenerative hyperplasia, portal hypertension
Rare (0.01% to 0.1%): Portal hypertension, hepatic failure, nodular regenerative hyperplasia[Ref]
Hypersensitivity
Common (1% to 10%): Hypersensitivity[Ref]
Immunologic
Common (1% to 10%): Immunogenicity[Ref]
Metabolic
Very common (10% or more): Hypokalemia (11%)
Common (1% to 10%): Blood alkaline phosphatase increased[Ref]
Musculoskeletal
Very common (10% or more): Musculoskeletal pain (36%), arthralgia (19%), myalgia (13%)[Ref]
Nervous system
Very common (10% or more): Headache (28%), peripheral neuropathy (23%), asthenia, chills
Common (1% to 10%): Dizziness, dysgeusia, memory impairment[Ref]
Ocular
Common (1% to 10%): Dry eye, conjunctivitis, blurred vision, lacrimation increased[Ref]
Other
Very common (10% or more): Fatigue (37%), pyrexia (23%), asthenia (16%), chills (10%)[Ref]
Psychiatric
Very common (10% or more): Insomnia (12%)[Ref]
Respiratory
Very common (10% or more): Epistaxis (24%), cough (20%), dyspnea (13%)
Uncommon (0.1% to 1%): Pneumonitis[Ref]
Local
Uncommon (0.1% to 1%): Injection site extravasation, infusion-related reactions[Ref]
References
1. Cerner Multum, Inc. "Australian Product Information." O 0
2. "Product Information. Kadcyla (ado-trastuzumab)." Genentech, South San Francisco, CA.
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
More about ado-trastuzumab emtansine
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: HER2 inhibitors
Consumer resources
Other brands: Kadcyla